Clinical trial
A Multi-center Phase II Trial of Capecitabine in Combination With Oxaliplatin (Xelox) as First Line Chemotherapy in Patients With Metastatic Nasopharyngeal Carcinoma (NPC)
NCT00363831 is registered in ClinicalTrials.gov with The University of Hong Kong as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multi-center Phase II Trial of Capecitabine in Combination With Oxaliplatin (Xelox) as First Line Chemotherapy in Patients With Metastatic Nasopharyngeal Carcinoma (NPC)
- Lead sponsor
- The University of Hong Kong
- Phase
- Phase 2
- Overall status
- Unknown status
- Start date
- July 31, 2006
- Completion date
- Not reported
- Enrollment
- 42 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.